369. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445- 1451.
370. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-734.
371. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006;44:703-712.
372. Yim HJ. Management of antiviral-resistant chronic hepatitis B virus infection. Korean J Gastroenterol 2008;51:346-359.
373. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
374. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine- resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-313.
375. Lampertico P, Marzano A, Levrero M, Santantonio T, Di Marco V, Brunette M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. [Abstract]. J Hepatol 2007;46(Suppl 1):S191.
376. Gaia S, Barbon V, Smedile A, Olivero A, Carenzi S, Lagget M, et al. Lamivudine-resistant chronic hepatitis B: An observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008;48:540-547.
377. Lim YS, Lee TH, Heo NY, Shim JH, J. LH, Suh DJ. Entecavir plus adefovir combination for chronic hepatitis B patients after failure of nucleos(t)ide analogue. [Abstract]. Korean J Gastroenterol 2010;56:A293.
378. Ahn SH, Kweon YO, Paik SW, Sohn JH, Lee KS, Kim DJ, et al. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatol Int 2011 Oct 12. [Epub ahead of print].
379. Yoon E, Yim HJ, Lee HJ, Lee SJ, Suh SJ, Hyun JJ, et al. The initial antiviral efficacy of telbivudine and adefovir combination therapy in patients with various settings of antiviral resistance. [Abstract]. Korean J Hepatol 2011;17(Suppl 3):S87.
380. van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425.
381. van Bommel F, Zollner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44:318-325.
382. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.
383. Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int 2008;2:244-249.
384. Patel N, Amarapurkar D. Tenofovir rescue therapy for patients with viral resistance to lamivudine and/or adefovir treatment. [Abstract]. Hepatol Int;2010(Suppl 1):4;161.
385. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine- refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049.
386. Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis

<PAGE>116